Allometric scaling is widely used to predict human pharmacokinetic parameters from preclinical
species, and many different approaches have been proposed over the years to improve …

Background Primary Sjögren's syndrome is an autoimmune disease that presents as dryness
of the mouth and eyes due to impairment of the exocrine glands. To our knowledge, no …

This study was designed to investigate the human absorption, disposition, and mass balance
of 14 C-brivaracetam, a novel high affinity SV2A ligand with potent anticonvulsant activity. …

Iscalimab is a fully human, CD40 pathway blocking, nondepleting monoclonal antibody being
developed as an immunosuppressive agent. We describe a first-in-human, randomized, …

Like any other drugs, antiallergic medications can be associated with large inter- and
intraindividual variability in their disposition. The best-documented examples belong to the H1 …

The CD40-CD154 costimulatory pathway is essential for T cell–dependent immune responses,
development of humoral memory, and antigen presenting cell function. These immune …

Context The CD40-CD154 co-stimulatory pathway plays an important role in the pathogenesis
of Graves disease (GD) by promoting autoreactive B-cell activation. Objective Evaluate …

Background Increased morbidity in many patients with myasthenia gravis (MG) on long-term
immunosuppression highlights the need for improved treatments. The aim of this study is to …

Background and objective Anti‐IL‐17A IgG/κ monoclonal antibody CJM112 binds both IL‐17A
and IL‐17AF. The purpose of this First‐in‐Human study was to assess CJM112 effects on …

CFZ533 is a pathway blocking, nondepleting anti-CD40 antibody that is in clinical development
for inhibition of transplant organ rejection and therapy for autoimmune diseases. A 26-…